Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Tech Reporter.
Press releases published on May 2, 2025
EXA Infrastructure selects Nokia to expand international connectivity network capabilities
GlobeNewswire
·
May 2, 2025
Press Release EXA Infrastructure selects Nokia to expand international connectivity network capabilities EXA Infrastructure’s modernized network will support data center connectivity with significantly lower cost and power per bit to keep up with demand in …
EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025
GlobeNewswire
·
May 2, 2025
Glasgow, Scotland – 2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE Phase 1b trial evaluating EBX-102, …
Polana Launches AI-Driven DeFi Platform and Starts POLAI Token ICO/Presale
GlobeNewswire
·
May 2, 2025
Phoenix, AZ, May 02, 2025 (GLOBE NEWSWIRE) -- Polana Labs (POLAI), an AI-powered DeFi platform, has officially launched, boasting automated, AI-driven investment tools that help users optimize their crypto portfolios. Simultaneously with its launch, Polana …
Golar entered into 20-year agreements for 5.95mtpa nameplate capacity in Argentina – one of the world’s largest FLNG development projects.
GlobeNewswire
·
May 2, 2025
Golar LNG Limited (“GLNG”, “Golar” or “the Company”) is pleased to announce the Final Investment Decision (“FID”) and fulfilment of all conditions precedent for the 20-year re-deployment charter of the FLNG Hilli Episeyo (“FLNG Hilli” or “Hilli”), first …
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
GlobeNewswire
·
May 2, 2025
Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found here. …
301,521 Orion Corporation A shares converted into B shares
GlobeNewswire
·
May 2, 2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 2 MAY 2025 at 9.00 EEST 301,521 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles …
301 521 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
GlobeNewswire
·
May 2, 2025
ORION OYJ PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT 2.5.2025 KLO 9.00 301 521 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 301 521 …
Aalberts N.V.: Aalberts reports first quarter 2025 results
GlobeNewswire
·
May 2, 2025
Utrecht, 2 May 2025 Aalberts reports first quarter 2025 results In the first quarter Aalberts realised EUR 778.3 million revenue, which translates into 3.3% organic revenue decline compared to the first quarter of last year. We realised EUR 105.7 million …
Aduro beauftragt Siemens mit der Bereitstellung fortschrittlicher Automatisierung für Hydrochemolytic™-Pilotanlage
GlobeNewswire
·
May 2, 2025
London, Ontario, May 02, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. („Aduro“ oder das „Unternehmen“) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), ein Unternehmen für saubere Technologien, das die Kraft der Chemie nutzt, um minderwertige Rohstoffe wie …
Aduro fait appel à Siemens pour l’automatisation avancée de son usine pilote Hydrochemolytic™
GlobeNewswire
·
May 2, 2025
LONDON, Province de l’Ontario, 02 mai 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc., ci-après « Aduro » ou la « Société », (NASDAQ :ADUR) (CSE :ACT) (FSE : 9D5), une société de technologie propre qui recycle chimiquement les matières premières de …
OBI Pharma gibt bekannt, dass die US-Arzneimittelbehörde FDA den IND-Antrag für eine Phase-1/2-Studie mit OBI-902, einem Trop-2-gerichteten ADC, genehmigt hat
GlobeNewswire
·
May 2, 2025
TAIPEI, Taiwan, May 02, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. („OBI“), ein Onkologieunternehmen in der klinischen Phase (4174.TWO), hat heute bekannt gegeben, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) den Antrag …
OBI Pharma reçoit l’approbation de la FDA à la suite de sa demande d’étude clinique de la Phase I/II pour OBI-902, un CAM ciblant Trop-2
GlobeNewswire
·
May 2, 2025
TAIPEI, Taïwan, 02 mai 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (« OBI »), un laboratoire d’oncologie au stade clinique (4174.TWO), annonce ce jour que l’Agence américaine des produits alimentaires et médicamenteux, la Food and Drug Administration, ou « …
Snail Games 发布捷报，2025 年 4 月攻势如虹：王牌 IP 开疆拓土，独立恐怖 IP 新作面世，战略发行高歌猛进
GlobeNewswire
·
May 2, 2025
卡尔弗城，加利福尼亚州, May 02, 2025 (GLOBE NEWSWIRE) -- 作为全球领先的互动数字娱乐独立开发商和发行商，Snail, Inc. (Nasdaq: SNAL，以下简称“Snail Games”或“公司”) 今日公布了其 2025 年 4 月的卓越战绩，包括 ARK 系列的持续扩张，Bellwright 里程碑式的内容更新，以及该公司的独立游戏发行品牌 Wandering Wizard 旗下多款 IP 的发布。 ARK 系列内容焕新，魅力加倍 Snail Games …
Snail Games 報告稱 2025 年 4 月主要特許經營的擴展、新獨立恐怖 IP 發布及策略性發布增長帶來強大動力
GlobeNewswire
·
May 2, 2025
卡爾弗城，加州, May 02, 2025 (GLOBE NEWSWIRE) -- 全球領先的互動數碼娛樂獨立開發商和發行商 Snail, Inc. (Nasdaq: Snal) (「Snail Games」或「公司」)，今天重點介紹了其產品組合在 2025 年 4 月份的主要進程，包括 ARK 系列的擴展、Bellwright 的內容進程，以及公司獨立發行商品牌 Wandering Wizard 旗下的多個 IP 發布。 ARK 系列憑藉全新內容得以更上一層樓 Snail Games …
Equinor sells the Peregrino field for USD 3.5 billion
GlobeNewswire
·
May 2, 2025
Equinor Brasil Energia Ltda., a subsidiary of Equinor (OSE: EQNR, NYSE: EQNR), has entered into agreements(1) with Brazilian company Prio Tigris Ltda., a subsidiary of PRIO SA (PRIO3.SA) for a sale of its 60% operated interest in the Peregrino field in …
Equinor selger Peregrino-feltet for 3,5 milliarder USD
GlobeNewswire
·
May 2, 2025
Equinor Brasil Energia Ltda., et datterselskap av Equinor ASA (OSE:EQNR, NYSE: EQNR), har inngått avtaler(1) om salg av sin egenopererte eierandel på 60 prosent i Peregrino-feltet i Brasil med det brasilianske selskapet Prio Tigris Ltda. (PRIO3.SA). PRIO, …
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
GlobeNewswire
·
May 2, 2025
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial Full results from the trial will be submitted for presentation at an upcoming …
ECG INVESTOR ALERT: Kirby McInerney LLP Notifies Everus Construction Group, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
GlobeNewswire
·
May 2, 2025
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the June 3, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Everus …
UCTT INVESTOR ALERT: Kirby McInerney LLP Reminds Ultra Clean Holdings, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
GlobeNewswire
·
May 2, 2025
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of the approaching May 23, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired …
Brazil Potash Announces Participation in Upcoming Investor Conferences and Going Concern Qualification
GlobeNewswire
·
May 2, 2025
MANAUS, Brazil, May 01, 2025 (GLOBE NEWSWIRE) -- Brazil Potash Corp. ("Brazil Potash" or the "Company") (NYSE-American: GRO), a mineral exploration and development company with a critical mineral potash mining project, the Autazes Project, today announced …